Drug Profile
EN 100
Latest Information Update: 24 Apr 2007
Price :
$50
*
At a glance
- Originator eNOS Pharmaceuticals
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Alzheimer's disease; Cardiovascular disorders; Stroke
Most Recent Events
- 24 Apr 2007 Discontinued - Phase-I for Cardiovascular disorders in USA (PO)
- 24 Apr 2007 Discontinued - Preclinical for Alzheimer's disease in USA (PO)
- 24 Apr 2007 Discontinued - Preclinical for Stroke in USA (PO)